Pulling SEC filings + quote and writing the call…
ARQT
Arcutis Biotherapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $0.03 EPS, $120M rev
Last earnings +0.1% on 2026-02-25
$26.21
▼ -0.04%$26.21▲ +95.60%
over 1Y
L $13.26EODHDH $31.20
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-0.0%
1W+6.6%
1M+34.4%
3M+14.4%
YTD-9.6%
1Y+95.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Revenue grew 91.3% YoY; but unprofitable (net margin -4.3%).
Arcutis Biotherapeutics, Inc. shows $376M in FY2025 revenue (+91.3% YoY), a -4.3% net margin, and -8.5% ROE.
Sources: SEC EDGAR (CIK 0001787306, latest 10-Q filed 2026-05-06) · EODHD · as of 6/22/2026, 11:13:11 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.